BIO-key International financials
$3.12+85.71%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.9M | $6.9M | $7.8M | $7.0M | $5.1M | $2.8M | $2.3M | $4.0M | $6.3M |
| Gross profit | $4.6M | $5.6M | $1.4M | $4.6M | $3.4M | $2.0M | -$193.7K | -$119.6K | $3.1M |
| Gross margin | 76.9% | 81.4% | 18.5% | 65.2% | 67.3% | 72.0% | −8.5% | −3.0% | 48.6% |
| Operating income | -$6.8M | -$4.0M | -$8.8M | -$9.9M | -$4.9M | -$5.2M | -$13.5M | -$6.9M | -$4.3M |
| Net income | -$7.2M | -$4.3M | -$8.5M | -$11.9M | -$5.1M | -$9.8M | -$14.6M | -$8.5M | -$5.0M |
| Net margin | −120.6% | −62.1% | −109.9% | −169.7% | −99.0% | −345.0% | −643.4% | −210.1% | −80.0% |
| Diluted EPS | $-10.77 | $-20.88 | $-152.10 | $-272.60 | $-117.00 | $-374.40 | $-1477.80 | $-1051.20 | $-1094.40 |
| EBITDA | -$4.0M | -$3.6M | -$8.2M | -$7.6M | -$4.7M | -$5.0M | -$5.6M | -$5.3M | -$2.7M |
| Operating cash flow | -$4.7M | -$2.9M | -$3.8M | -$6.2M | -$9.0M | -$5.0M | -$1.9M | -$1.6M | -$2.5M |
| Free cash flow | -$4.7M | -$2.9M | -$3.8M | -$6.3M | -$9.0M | -$5.0M | -$1.9M | -$1.7M | -$2.6M |
| Diluted shares | 0.7M | 0.2M | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.7M | $437.6K | $511.4K | $2.6M | $7.8M | $17.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | $512.8K |
| Total debt | $654.6K | $1.7M | $327.5K | $3.0M | $0.00 | $232.0K |
| Total assets | $8.3M | $8.6M | $4.5M | $11.3M | $17.8M | $22.5M |
| Total liabilities | $3.2M | $4.8M | $3.5M | $6.0M | $2.2M | $2.2M |
| Shareholders' equity | $5.1M | $3.8M | $1.1M | $5.3M | $15.6M | $20.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology